163 related articles for article (PubMed ID: 31938346)
41. Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells.
Guo R; Wu K; Chen J; Mo L; Hua X; Zheng D; Chen P; Chen G; Xu W; Feng J
Cell Physiol Biochem; 2013; 32(6):1668-80. PubMed ID: 24356372
[TBL] [Abstract][Full Text] [Related]
42. Survivin Inhibitors Mitigate Chemotherapeutic Resistance in Breast Cancer Cells by Suppressing Genotoxic Nuclear Factor-
Wang W; Zhang B; Mani AM; Wu Z; Fan Y; Li W; Wu ZH
J Pharmacol Exp Ther; 2018 Jul; 366(1):184-193. PubMed ID: 29735611
[TBL] [Abstract][Full Text] [Related]
43. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
44. Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody.
Camirand A; Fadhil I; Luco AL; Ochietti B; Kremer RB
Am J Cancer Res; 2013; 3(5):500-8. PubMed ID: 24224127
[TBL] [Abstract][Full Text] [Related]
45. Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin:
Eliaa SG; Al-Karmalawy AA; Saleh RM; Elshal MF
ACS Pharmacol Transl Sci; 2020 Dec; 3(6):1330-1338. PubMed ID: 33344906
[TBL] [Abstract][Full Text] [Related]
46. Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells.
Shrestha S; Sorolla A; Fromont J; Blancafort P; Flematti GR
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30275391
[TBL] [Abstract][Full Text] [Related]
47. DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis.
Cao S; Long X; Xiao L; Zhang P; Shen M; Chen F; Bao C; Zhong X; Luo T; Ye F
Front Oncol; 2024; 14():1356778. PubMed ID: 38549944
[TBL] [Abstract][Full Text] [Related]
48. Morin Sensitizes MDA-MB-231 Triple-Negative Breast Cancer Cells to Doxorubicin Cytotoxicity by Suppressing FOXM1 and Attenuating EGFR/STAT3 Signaling Pathways.
Maharjan S; Lee MG; Kim SY; Lee KS; Nam KS
Pharmaceuticals (Basel); 2023 Apr; 16(5):. PubMed ID: 37242455
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
50. High Expression of G6PD Increases Doxorubicin Resistance in Triple Negative Breast Cancer Cells by Maintaining GSH Level.
Luo M; Fu A; Wu R; Wei N; Song K; Lim S; Luo KQ
Int J Biol Sci; 2022; 18(3):1120-1133. PubMed ID: 35173543
[TBL] [Abstract][Full Text] [Related]
51. Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
Choi J; Lee HJ; Yoon S; Ryu HM; Lee E; Jo Y; Seo S; Kim D; Lee CH; Kim W; Ha JY; Kim SY; Gong G; Jung KH; Park SR; Kim SW; Park KS; Lee DH
Am J Cancer Res; 2020; 10(9):2878-2894. PubMed ID: 33042623
[TBL] [Abstract][Full Text] [Related]
52. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide.
Wang S; Kotamraju S; Konorev E; Kalivendi S; Joseph J; Kalyanaraman B
Biochem J; 2002 Nov; 367(Pt 3):729-40. PubMed ID: 12139490
[TBL] [Abstract][Full Text] [Related]
53. Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2.
Gao Z; Shi M; Wang Y; Chen J; Ou Y
Pathol Res Pract; 2019 Jul; 215(7):152422. PubMed ID: 31079851
[TBL] [Abstract][Full Text] [Related]
54. Phenylmethimazole and a thiazole derivative of phenylmethimazole inhibit IL-6 expression by triple negative breast cancer cells.
Noori MS; O'Brien JD; Champa ZJ; Deosarkar SP; Lanier OL; Qi C; Burdick MM; Schwartz FL; Bergmeier SC; McCall KD; Goetz DJ
Eur J Pharmacol; 2017 May; 803():130-137. PubMed ID: 28343970
[TBL] [Abstract][Full Text] [Related]
55. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
56. Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.
Woo SM; Kim AJ; Choi YK; Shin YC; Cho SG; Ko SG
Phytother Res; 2016 Nov; 30(11):1817-1823. PubMed ID: 27476488
[TBL] [Abstract][Full Text] [Related]
57. Forskolin improves sensitivity to doxorubicin of triple negative breast cancer cells via Protein Kinase A-mediated ERK1/2 inhibition.
Illiano M; Sapio L; Salzillo A; Capasso L; Caiafa I; Chiosi E; Spina A; Naviglio S
Biochem Pharmacol; 2018 Jun; 152():104-113. PubMed ID: 29574069
[TBL] [Abstract][Full Text] [Related]
58. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
59. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
60. CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy.
Liu X; Zhang G; Yu T; Liu J; Chai X; Yin D; Zhang C
Int J Biol Macromol; 2023 Oct; 250():126147. PubMed ID: 37544559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
